🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Larry Robbins’s IDXX Holdings & Trades

First Buy
Q3 2026
Duration Held
1 Quarters
Largest Add
Q3 2026
+1,200 Shares
Current Position
1,200 Shares
$626,628 Value

Larry Robbins's IDXX Position Overview

Larry Robbins (via Glenview Capital Management, LLC) currently holds 1,200 shares of IDEXX Laboratories, Inc. (IDXX) worth $626,628, representing 0.01% of the portfolio. First purchased in 2026-Q3, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Larry Robbins has initiated a new position in IDXX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Larry Robbins's IDEXX Laboratories (IDXX) Holding Value Over Time

Track share changes against reported price movement

Quarterly IDEXX Laboratories (IDXX) Trades by Larry Robbins

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +1,200 New Buy 1,200 $522.19

Larry Robbins's IDEXX Laboratories Investment FAQs

Larry Robbins first purchased IDEXX Laboratories, Inc. (IDXX) in Q3 2026, acquiring 1,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Larry Robbins has held IDEXX Laboratories, Inc. (IDXX) for 1 quarters since Q3 2026.

Larry Robbins's largest addition to IDEXX Laboratories, Inc. (IDXX) was in Q3 2026, adding 1,200 shares worth $626,628.

According to the latest 13F filing for Q3 2026, Larry Robbins's firm, Glenview Capital Management, LLC, owns 1,200 shares of IDEXX Laboratories, Inc. (IDXX), valued at approximately $626,628.

As of the Q3 2026 filing, IDEXX Laboratories, Inc. (IDXX) represents approximately 0.01% of Larry Robbins's publicly disclosed stock portfolio, making it one of their key holdings.

Larry Robbins's peak holding in IDEXX Laboratories, Inc. (IDXX) was 1,200 shares, as reported at the end of Q3 2026.